Eikon Therapeutics (EIKN) began trading on the Nasdaq on Thur 5 Feb 26

• Sector: HealthcareIndustry: Biotechnology
• Incorporated in 2019 
• HQ in Millbrae, California
• https://www.eikontx.com/

Eikon Therapeutics priced 21,177,600 share IPO (upgraded from 17.7 mln prior) at $18.00 per share, at the high end of the $16-18 expected range

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

Ticker: EIKN

At $381 million, Eikon looks set to be the largest biotech IPO since 2024, overtaking Aktis Oncology’s $318 million offering last month.

The California-based company has already set out its plans for spending the proceeds, with the biggest priority labeled as the clinical development of EIK1001. The toll-like receptor 7 and 8 agonist immune modulator, which Eikon acquired from Seven and Eight Biopharmaceuticals, is currently being tested in a phase 2/3 trial in combination with Keytruda for advanced melanoma and a phase 2/3 study for non-small cell lung cancer.

Behind EIK1001 is a pair of PARP1 inhibitors, dubbed EIK1003 and EIK1004, which Eikon licensed from Chinese biotech Impact Therapeutics. These candidates are being trialed in phase 1/2 studies for ovarian, breast, prostate and pancreatic cancers, with EIK1004 also being assessed against brain metastases and primary brain malignancies due to its ability to cross the blood-brain barrier.

The fourth clinical candidate is an in-house WRN helicase inhibitor called EIK1005, which is in phase 1/2 development for solid tumors.

Galaxy Digital (GLXY) reported earnings on Tue 3 Feb 26 (b/o)

• Galaxy Digital reports fiscal Q4 2025 results with non-GAAP EPS of -$1.08 and revenue of $10.2B, missing estimates; an SEC filing also shows a Q4 net loss of $482M, a full-year 2025 net loss of $241M, and equity capital up 38% to $3.0B as of year-end 2025.

  

Fat Brands (FAT) : suspension of Nasdaq trading

•  FAT Brands spun off its Twin Peaks and Smokey Bones chains as Twin Hospitality Group (ticker: TWNP) in January 2025 to help pay down mounting debt. 
• FAT Brands' stock  approaches the February 4 suspension of Nasdaq trading, directly resulting from the company's voluntary Chapter 11 bankruptcy filing on January 26, 2026. The delisting notice, issued by Nasdaq on January 28, cites non-compliance due to the bankruptcy and prior failure to maintain a $1 share price for 30 consecutive days. This has heightened investor concerns over liquidity and shareholder value in the restructuring process, which aims to address over $1.3 billion in debt through asset sales and negotiations. Recent volatility, including a prior surge on speculative trading, reversed as the delisting date nears, with no new positive developments reported to counter the negative implications.